Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Debt Ratio (2020 - 2025)

Historic Debt Ratio for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to 0.04.

  • Gain Therapeutics' Debt Ratio rose 1237.8% to 0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.04, marking a year-over-year increase of 1237.8%. This contributed to the annual value of 0.04 for FY2024, which is 1853.02% up from last year.
  • Latest data reveals that Gain Therapeutics reported Debt Ratio of 0.04 as of Q3 2025, which was up 1237.8% from 0.05 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Debt Ratio registered a high of 0.05 during Q2 2025, and its lowest value of 0.02 during Q1 2021.
  • For the 5-year period, Gain Therapeutics' Debt Ratio averaged around 0.03, with its median value being 0.03 (2023).
  • Per our database at Business Quant, Gain Therapeutics' Debt Ratio plummeted by 7683.19% in 2021 and then skyrocketed by 8683.0% in 2023.
  • Over the past 5 years, Gain Therapeutics' Debt Ratio (Quarter) stood at 0.02 in 2021, then surged by 40.59% to 0.03 in 2022, then grew by 21.87% to 0.03 in 2023, then increased by 18.53% to 0.04 in 2024, then grew by 6.93% to 0.04 in 2025.
  • Its Debt Ratio was 0.04 in Q3 2025, compared to 0.05 in Q2 2025 and 0.04 in Q1 2025.